Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

IMCR vs DYN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMCR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

IMCR Overall Winner 6-Pillar Tally: IMCR 4 – 2 DYN Matrix Metrics: IMCR 5 – 5 DYN

As of Nov 20, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). IMCR carries a Unified Composite Score of 44.1/100 (HOLD) at $26.41 (20.8x Forward P/E, -2.2% operating margin), whereas DYN carries 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1); meanwhile DYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMCR vs DYN
IMCR NASDAQ Head-to-Head Winner
Immunocore Holdings plc American Depositary Shares
Biological Products, (No Disgnostic Substances)
$26.41
-0.83% 1D
Market Cap $1.4B
TTM Revenue $429M
Forward P/E 20.8x
Beta / 30D Vol 0.63β · 49% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 33.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.4%), weak momentum, RSI 33
RSI-14: 33.1 · SMA20: $29.97 · SMA50: $30.37
DYN NASDAQ
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$15.50
-3.31% 1D
Market Cap $3.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 25.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $17.08 · SMA50: $16.55

6-Pillar Scorecard Institutional Category Breakdown (IMCR 4 – 2 DYN)

Columns: Metric · IMCR · DYN
1. Valuation Multiples IMCR
Forward P/E 20.8x N/M
Trailing P/E 20.8x N/M
PEG Ratio N/M 0.19x
EV / Revenue 3.2x N/M
2. Growth & Scale DYN
Revenue Growth (YoY) -1.4% +0.0%
Earnings Growth (YoY) +150.0% +0.0%
TTM Revenue (USD) $429M N/A
Market Cap $1.4B $3.0B
3. Profitability & Quality DYN
Gross Margin 34.5% N/A
Operating Margin -2.2% 0.0%
Net Profit Margin -7.5% 0.0%
Return on Equity (ROE) -7.9% -74.6%
4. Balance Sheet & Cash Flow IMCR
Cash Generation (TTM) -$5.4M EBITDA -$569M
Cash Flow Margin -1.3% EBITDA Mgn N/A
Net Cash / Leverage $8.13 Book/Sh · -7.9% ROE $694M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMCR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 56.7% (10th %ile) 58.2% (9th %ile)
Put/Call OI Skew Thin ADR Chain 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IMCR
OpEx & R&D Intensity 36.7% of Rev ($158M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMCR (5) vs DYN (5)
Institutional Metric IMCR DYN Criterion Row Edge
Market Capitalization
Scale
$1.4B $3.0B Larger Scale DYN
Trailing P/E Ratio
Valuation
20.8x N/M Lower Multiple IMCR
Forward P/E Ratio
Valuation
20.8x N/M Lower Multiple IMCR
Revenue Growth (YoY)
Growth
-1.4% +0.0% Higher Growth DYN
Operating Margin (TTM)
Profitability
-2.2% 0.0% Higher Margin DYN
Net Profit Margin
Profitability
-7.5% 0.0% Higher Margin DYN
Return on Equity (ROE)
Capital Efficiency
-7.9% -74.6% Higher ROE IMCR
52-Week Range Position
Momentum
5% ($26–$41) 11% ($14–$27) Stronger Trend DYN
Beta / 30D Volatility
Risk Regime
0.63β · 49% Vol 1.55β · 55% Vol Lower Realized Risk IMCR
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 39.9 / 100 (SELL) Higher Composite IMCR
Trailing 12M Revenue (USD)
Operating Scale
$429M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 0.19x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.4M EBITDA ($8.13 Book/Sh · -7.9% ROE) -$569M ($694M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DYN +16.07 pp
IMCR: -17.78% · DYN: -1.71%
3M Horizon IMCR +12.5 pp
IMCR: -27.86% · DYN: -40.36%
6M Horizon IMCR +2.38 pp
IMCR: -8.39% · DYN: -10.77%
1Y Horizon DYN +6.91 pp
IMCR: -31.67% · DYN: -24.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMCR vs DYN. Trailing 12-month operating profitability (IMCR -2.2% vs DYN 0.0%) and valuation multiples (IMCR 20.8x vs DYN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$429M
Gross Margin34.5%
Op. Margin-2.2%
ROE / Fwd P/E-7.9% · 20.8x
DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.7%
IV Percentile 10th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DYN BREAKDOWN
72d in phase · OBV DISTRIBUTION
Current IV 58.2%
IV Percentile 9th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $15.87 · IV 56.7%

DYN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,587)

Compare $1,587 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 56.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $16 / $17.5 Bull Call Spread

Buy 2x $16C · Sell 2x $17.5C · 30d

Net Entry $200 Debit
T+5d @ +5% Move +$24 (+12%)
Max Risk / Buffer $200 Capped
5d Edge & Liquidity 0.5x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $16 / $15 Bear Put Spread

Buy 2x $16P · Sell 2x $15P · 30d

Net Entry $136 Debit
T+5d @ -5% Drop +$22 (+16%)
Max Risk / Buffer $136 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment 36.7% of Rev ($158M)
90D Engineering Disclosures 0 Published
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMCR vs DYN Key Questions & Quantitative Answers

As of Nov 20, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). IMCR carries a Unified Composite Score of 44.1/100 (HOLD) at $26.41 (20.8x Forward P/E, -2.2% operating margin), whereas DYN carries 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1); meanwhile DYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DYN leads the Growth & Scale pillar: IMCR posts -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin), compared with DYN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMCR generates $429M in USD-normalized revenue versus N/A for DYN. In operating R&D and SG&A reinvestment, IMCR deploys 36.7% of Rev ($158M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DYN.

IMCR screens cheaper on headline valuation multiples. IMCR trades at 20.8x Forward P/E, 20.8x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-1.3% EBITDA margin), whereas DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMCR (-7.9% ROE) versus DYN (-74.6% ROE) capital efficiency.

In options market volatility and institutional positioning, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 49% Vol realized risk). By comparison, DYN carries 58.2% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.